Table 1.
TIB and prognosis of cancer patients.
| Tumor type | Related mechanism | Prognostic evaluation |
|---|---|---|
| Breast cancer | ||
| TLS formation, CD20+ TIB, IBC and TN IBC: CD20+ TIL/PD-L1+ TIL | Good | |
| DCIS: CD20+ TIB | Bad | |
| Node-negative breast cancer | Unrelated | |
|
| ||
| Ovarian cancer | ||
| High-grade serous ovarian tumor: correlation of antigen-experienced but atypical CD27–CD20+ TIL and CD8+ T cell | Good | |
| CD138highCD20+ TIB | Bad | |
|
| ||
| Melanoma | ||
| TLS formation, high CD20+ TIB, expression of CD20+ TIB in close proximity to CD3+ T cells | Good | |
| Cutaneous melanoma: high CD20+ TIB, CD138+ plasma cells | Bad | |
|
| ||
| Colorectal cancer | TLS formation, CD20+, CD138+, IGKC+ tumor-infiltrating B cells and plasma cells | Good |
|
| ||
| Gastric cancer | TLS formation | Good |
|
| ||
| Bladder cancer | MIBC: CD19+ TIB serve as APC to activate CD4+ TIT | Good |
|
| ||
| Prostate cancer | Higher TIB | Bad |
|
| ||
| Lung cancer | ||
| Adenocarcinoma: CD138+ plasma cells, IGKC+ | Good | |
| NSCLC: CD20+ B cells and CD79α+p63+ plasma cells | Bad | |
| NSCLC | Unrelated | |
|
| ||
| Liver cancer | TLS formation | Good |
| HCC: synergistic effect of CD20+ TIB and CD8+ T cell | ||
Special tumor subtypes are shown in bold.